§ Lord Clement-Jones
asked Her Majesty's Government:
In the light of the recent discontinuation of human-derived follicle-stimulating hormone (Metrodin High Purity) by the Committee on Safety of Medicines because of the posed risk of vCJD, whether they have assessed the cost of possible compensation claims from transfusion of vCJD through United Kingdom-sourced fresh frozen plasma. [HL2554]
§ Baroness Andrews
No specific assessment has been made of the possible compensation claims from transfusion of variant Creutzfeldt-Jakob Disease through United Kingdom-sourced fresh frozen plasma. There is no evidence world wide that CJD or vCJD has ever been transmitted through blood or blood products although the theoretical risk cannot be ruled out.